Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2010 - 2024)

Ani Pharmaceuticals has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting $7.6 million for Q4 2024.

• Asset Writedowns and Impairment for Q4 2024 came in at $7.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $7.6 million (changed 0.0% YoY), and the FY2025 annual result was $767000.0, down 89.91% from the prior year.
• Asset Writedowns and Impairment came in at $7.6 million for Q4 2024 at Ani Pharmaceuticals, up from -$1000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.6 million in Q4 2024 to a low of -$1000.0 in Q3 2022.
• The 4-year median for Asset Writedowns and Impairment is $341000.0 (2020), against an average of $2.1 million.
• Across the five-year window, Asset Writedowns and Impairment soared 354.67% in 2020 and soared 596.19% in 2021, its largest moves.
• Ani Pharmaceuticals' Asset Writedowns and Impairment stood at $341000.0 in 2020, then jumped by 596.19% to $2.4 million in 2021, then tumbled by 100.04% to -$1000.0 in 2022, then jumped by 760100.0% to $7.6 million in 2024.
• The last three Asset Writedowns and Impairment figures came in at $7.6 million (Q4 2024), -$1000.0 (Q3 2022), and $2.4 million (Q4 2021), per Business Quant data.